Comparative Pharmacology
Head-to-head clinical analysis: BRIMONIDINE TARTRATE TIMOLOL MALEATE versus INDERAL LA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRIMONIDINE TARTRATE TIMOLOL MALEATE versus INDERAL LA.
BRIMONIDINE TARTRATE; TIMOLOL MALEATE vs INDERAL LA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Brimonidine is a selective alpha-2 adrenergic receptor agonist that reduces aqueous humor production and increases uveoscleral outflow. Timolol is a non-selective beta-adrenergic receptor blocker that decreases aqueous humor production by inhibiting beta-2 receptors in the ciliary epithelium.
Propranolol is a non-selective beta-adrenergic receptor antagonist that competitively blocks beta-1 and beta-2 receptors, decreasing heart rate, myocardial contractility, and blood pressure; also inhibits renin release and reduces sympathetic outflow.
One drop of the fixed combination (0.2% brimonidine/0.5% timolol) in the affected eye(s) twice daily, approximately 12 hours apart.
Initial: 80 mg orally once daily; titrate to 120-160 mg once daily; maximum 640 mg/day.
None Documented
None Documented
Brimonidine: ~3 hours (terminal); timolol: ~4–6 hours (terminal). Clinical context: allows twice-daily dosing for brimonidine/timolol combination.
Terminal elimination half-life is 8-11 hours (range 4-16 hours) after oral administration. The extended-release formulation (INDERAL LA) results in a prolonged half-life of approximately 10 hours, allowing once-daily dosing.
Brimonidine: primarily renal (74% as unchanged drug); timolol: renal (20% unchanged, remainder as metabolites) and fecal (small amount).
Primarily hepatic metabolism with renal elimination of metabolites. Less than 1% excreted unchanged in urine. Biliary/fecal excretion of metabolites accounts for approximately 20% of eliminated dose.
Category A/B
Category C
Beta-Blocker
Beta-Blocker